Int. Immunopharmacol.
Maraviroc attenuates the pathogenesis of experimental autoimmune encephalitis.
Karampoor S, Zahednasab H, Amini R, Esghaei M, Sholeh M, Keyvani H
It has been shown that the blockade of chemokine receptor type 5 can dampen inflammatory reaction within the central nervous system (CNS). In the pres ...
Read More
Source: PubMed
Mult Scler Relat Disord
A method to compare prospective and historical cohorts to evaluate drug effects. Application to the analysis of early treatment effectiveness of intramuscular interferon-ß1a in multiple sclerosis patients.
Mallucci G, Patti F, Brescia Morra V, Buccafusca M, Moiola L, Amato MP, Ferraro E, Trojano M, Zaffaroni M, Mirabella M, Moscato G, Plewnia K, Zipoli V, Puma E, Bergamaschi R
Disease modifying therapy have changed the natural evolution of multiple sclerosis (MS), with efficacy demonstrated in randomized clinical trials. Sta ...
Read More
Source: PubMed
Mult Scler Relat Disord
In MS: Immunosuppression is passé.
Brod SA
Prolonged and significant alterations of the immune system by immunosuppression makes multiple sclerosis (MS) patients susceptible to opportunistic in ...
Read More
Source: PubMed
Mult Scler Relat Disord
Long term effect of delayed treatment on disability in patients with paediatric onset multiple sclerosis: A prospective Danish cohort study.
Kopp TI, Blinkenberg M, Petersen T, Sorensen PS, Magyari M
A consensus of early treatment with disease-modifying therapies (DMT) in multiple sclerosis (MS) has been reached based on several observational and e ...
Read More
Source: PubMed
Mult Scler Relat Disord
Comparison of health-related quality of life across treatment groups in individuals with multiple sclerosis.
Glanz BI, Zurawski J, Gonzalez CT, Shamah R, Ratajska A, Chitnis T, Weiner HL, Healy BC
Outcome measures typically used to evaluate disease modifying therapies (DMTs) provide important information regarding their effects on disease activi ...
Read More
Source: PubMed
